MX2019010913A - Analogos de deutetrabenazina, su preparacion y uso. - Google Patents

Analogos de deutetrabenazina, su preparacion y uso.

Info

Publication number
MX2019010913A
MX2019010913A MX2019010913A MX2019010913A MX2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A
Authority
MX
Mexico
Prior art keywords
deutetrabenazine
analogs
preparation
compositions
same
Prior art date
Application number
MX2019010913A
Other languages
English (en)
Spanish (es)
Inventor
Kerr Jim
Zhang Chengzi
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61873991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2019010913A publication Critical patent/MX2019010913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
MX2019010913A 2017-03-15 2018-03-15 Analogos de deutetrabenazina, su preparacion y uso. MX2019010913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Publications (1)

Publication Number Publication Date
MX2019010913A true MX2019010913A (es) 2020-01-20

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010913A MX2019010913A (es) 2017-03-15 2018-03-15 Analogos de deutetrabenazina, su preparacion y uso.

Country Status (20)

Country Link
US (5) US11813232B2 (cg-RX-API-DMAC10.html)
EP (1) EP3596077A1 (cg-RX-API-DMAC10.html)
JP (3) JP7608050B2 (cg-RX-API-DMAC10.html)
KR (2) KR20200003791A (cg-RX-API-DMAC10.html)
CN (1) CN110709398A (cg-RX-API-DMAC10.html)
AR (1) AR111182A1 (cg-RX-API-DMAC10.html)
AU (2) AU2018236336B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019018966A2 (cg-RX-API-DMAC10.html)
CA (1) CA3056612A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019002629A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019011271A2 (cg-RX-API-DMAC10.html)
EA (1) EA201992168A1 (cg-RX-API-DMAC10.html)
IL (1) IL269132A (cg-RX-API-DMAC10.html)
MX (1) MX2019010913A (cg-RX-API-DMAC10.html)
PE (1) PE20191819A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201908477QA (cg-RX-API-DMAC10.html)
TW (1) TWI772382B (cg-RX-API-DMAC10.html)
UA (1) UA127052C2 (cg-RX-API-DMAC10.html)
WO (1) WO2018170214A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201906326B (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI772382B (zh) 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
JP2022519007A (ja) 2018-12-13 2022-03-18 オースペックス ファーマシューティカルズ インコーポレイテッド 脳性麻痺におけるジスキネジアを処置するためのデューテトラベナジン
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
CN115916154A (zh) * 2020-06-10 2023-04-04 奥斯佩克斯医药公司 包括氘代丁苯那嗪的渗透剂型及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6362601B2 (ja) * 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
TWI772382B (zh) 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途

Also Published As

Publication number Publication date
NZ757789A (en) 2024-08-30
JP2020510073A (ja) 2020-04-02
JP2024050724A (ja) 2024-04-10
BR112019018966A2 (pt) 2020-04-22
JP7608050B2 (ja) 2025-01-06
US20220088006A1 (en) 2022-03-24
JP2023010754A (ja) 2023-01-20
CA3056612A1 (en) 2018-09-20
IL269132A (en) 2019-11-28
US11813232B2 (en) 2023-11-14
US12502385B2 (en) 2025-12-23
US20200016148A1 (en) 2020-01-16
EP3596077A1 (en) 2020-01-22
PE20191819A1 (es) 2019-12-27
JP7631572B2 (ja) 2025-02-18
WO2018170214A1 (en) 2018-09-20
TWI772382B (zh) 2022-08-01
UA127052C2 (uk) 2023-03-29
AR111182A1 (es) 2019-06-12
AU2018236336B2 (en) 2022-02-24
US20260144785A1 (en) 2026-05-28
TW201840317A (zh) 2018-11-16
CO2019011271A2 (es) 2020-02-28
KR20230003308A (ko) 2023-01-05
EA201992168A1 (ru) 2020-03-16
CN110709398A (zh) 2020-01-17
KR20200003791A (ko) 2020-01-10
US20220040170A1 (en) 2022-02-10
AU2022203369A1 (en) 2022-06-09
AU2018236336A1 (en) 2019-10-24
SG11201908477QA (en) 2019-10-30
US20180263972A1 (en) 2018-09-20
CL2019002629A1 (es) 2020-01-24
ZA201906326B (en) 2022-12-21
US11179386B2 (en) 2021-11-23
AU2022203369B2 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
MX2023008686A (es) Polinucleotidos moduladores.
TWD180147S (zh) 淨水器
MX385845B (es) Usos y composiciones de la flagelina
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
PH12017500836A1 (en) Transdermal formulations
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2015016603A (es) Composiciones de corticosteroides.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
CA3056612A1 (en) Analogs of deutetrabenazine, their preparation and use
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
MX2017014971A (es) Composiciones de sal mejoradas y metodo de preparacion de las mismas.
MX383313B (es) Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion
MX363625B (es) Composiciones dentifricas con estabilidad mejorada del fluoruro.
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
EA201890209A1 (ru) Композиция, содержащая танины
MX2016011416A (es) Composiciones de glicoproteinas sialiladas y usos de estas.
NZ721832A (en) Solid forms of tenofovir
MX2015015850A (es) Composiciones de sabor y fragancia que contienen tiopiran-carbaldehido.